Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

A Structure-Guided Drug Design Approach to Identify Fungal-Selective Yck2 Inhibitors

FY 2022-23

Summary
Fungal pathogens infect billions of people per year. A leading human fungal pathogen is Candida albicans, which can cause life-threatening systemic disease in immunocompromised individuals,with mortality rates of ~40%. These infections are notoriously difficult to treat and with the continued rise in drug-resistant infections,the development of novel antifungals is in urgent demand.Protein kinases have been established as promising targets in the development of drugs for various diseases,but their role as targets for antifungals has yet to be explored. Previous screening of a kinase inhibitor library revealed a 2,3-aryl-pyrazolopyridine compound, termed GW, as an inhibitor of the casein kinase 1 (CK1) family member, Yck2. Compromise of Yck2 function abrogates resistance to the newest class of antifungal drug,the echinocandins,and impairs C. albicans virulence traits in vitro. However, due to poor pharmacological properties, the efficacy of this compound was not able to be assessed in mammalian models of Candida infection. To examine 2,3-aryl-pyrazolopyridines as potential drug candidates, molecular derivatives were designed and synthesized. In this project, I will characterize the on-target activity, whole-cell antifungal activity, and fungal selectively of the newly-synthesized Yck2 inhibitors, using an in vitro kinase assay and whole cell fungal dose-response assay. I will examine the toxicity of the Yck2 inhibitors against mammalian cell lines to evaluate the molecules’ therapeutic potential. Finally, I will determine the stability of the compounds upon incubation with serum and mammalian microsomes. By optimizing the properties of these Yck2 inhibitors, this project might lead to the discovery of a novel class of antifungal drug targeting an important fungal kinase.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486033
Name
Yiu Bonnie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Structure-Guided Drug Design Approach to Identify Fungal-Selective Yck2 Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antifungal; Candida Albicans; Casein Kinase 1; Drug Design; Echinocandin; Fungal Pathogen; Funghi; Protein Kinase Inhibitor; Protein Kinases; Yck2
Abstract
Fungal pathogens infect billions of people per year. A leading human fungal pathogen is Candida albicans, which can cause life-threatening systemic disease in immunocompromised individuals,with mortality rates of ~40%. These infections are notoriously difficult to treat and with the continued rise in drug-resistant infections,the development of novel antifungals is in urgent demand.Protein kinases have been established as promising targets in the development of drugs for various diseases,but their role as targets for antifungals has yet to be explored. Previous screening of a kinase inhibitor library revealed a 2,3-aryl-pyrazolopyridine compound, termed GW, as an inhibitor of the casein kinase 1 (CK1) family member, Yck2. Compromise of Yck2 function abrogates resistance to the newest class of antifungal drug,the echinocandins,and impairs C. albicans virulence traits in vitro. However, due to poor pharmacological properties, the efficacy of this compound was not able to be assessed in mammalian models of Candida infection. To examine 2,3-aryl-pyrazolopyridines as potential drug candidates, molecular derivatives were designed and synthesized. In this project, I will characterize the on-target activity, whole-cell antifungal activity, and fungal selectively of the newly-synthesized Yck2 inhibitors, using an in vitro kinase assay and whole cell fungal dose-response assay. I will examine the toxicity of the Yck2 inhibitors against mammalian cell lines to evaluate the molecules’ therapeutic potential. Finally, I will determine the stability of the compounds upon incubation with serum and mammalian microsomes. By optimizing the properties of these Yck2 inhibitors, this project might lead to the discovery of a novel class of antifungal drug targeting an important fungal kinase.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yiu, Bonnie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~